Yılmaz, T.Akman, M.Tutluoğlu, BülentAfrasyap, LaleGöylüsün, VeliÇelik, N.2024-07-122024-07-121999Yilmaz, T., Akman, M., Tutluoğlu, B., Afrasyap, L., Göylüsün, V., ve Çelik, N. (1999). Plasma thrombomodulin levels in lung cancer patients. Panminerva medica, Edizioni Minerva Medica. 41(2), s.125-128 .0031-08081827-1898https://www.minervamedica.it/en/journals/panminerva-medica/article.php?cod=R41Y1999N02A0125https://hdl.handle.net/20.500.12415/4268BACKGROUND: Thrombomodulin (TM) is a glycoprotein and besides its anticoagulant property it is accepted as an onco developmental antigen. Considering these properties we hypothesised that active TMB might have a role in cancer cell behaviour. METHODS: We measured serum TMB levels by the enzyme immunoassay method in 40 patients with lung cancer and 20 healthy subjects. RESULTS: TMB levels were found as 54.6 +/- 11.5 in controls and 60.9 +/- 31.2 ng/ml in lung cancer patients TM levels were 59.4 +/- 24.2 ng/ml in 24 epidermoid carcinoma patients, 65 +/- 50.2 ng/ml in 10 small cell carcinoma patients and 60 +/- 18.4 ng/ml in 6 adenocarcinoma patients. Patients with stage 4 and distant metastasis had a value of 65 +/- 33.9 ng/ml. No significant differences were found between healthy subjects and cancer patients. Also the differences between 3 groups of patients were insignificant. CONCLUSIONS: It was concluded that serum TMB levels could not be accepted as a tumour marker in lung cancer patients.eninfo:eu-repo/semantics/openAccessArticle1282Q312541